Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980948 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
A Phase 1 study of Chronic Neuropathic Pain, sponsored by Sangamo Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 10
- Study locations
NCT06980948: Recruiting Phase 1 study of Chronic Neuropathic Pain, sponsored by Sangamo Therapeutics.
NCT06980948 is a Phase 1 study of Chronic Neuropathic Pain that is actively recruiting participants, run by Sangamo Therapeutics. The registered enrollment target is 27 participants, below the 80-participant average among 3 other Chronic Neuropathic Pain trials with a reported enrollment target (66% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06980948, a Phase 1 study of Chronic Neuropathic Pain, is actively recruiting participants, sponsored by Sangamo Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 10
- Study locations
Study Summary
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Primary Outcome
To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.
Conditions Studied
Interventions
- PROCEDURE Sham (No Treatment)
- GENETIC ST-503
Study Locations (10)
Arizona
- HonorHealth - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
New York
- Columbia University - New York
North Carolina
- University of North Carolina Medical Center - Chapel Hill
Tennessee
- Vanderbilt University - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-10 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
What NCT06980948 shows while recruiting
NCT06980948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 80-participant average among 3 other Chronic Neuropathic Pain trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Chronic Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions - of which Sham (No Treatment) is the first listed.
NCT06980948 lists 10 locations in 10 states (Arizona, Arkansas, Maryland).
Frequently Asked Questions
What is clinical trial NCT06980948 about?
NCT06980948 is a clinical study titled "Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)". This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due ...
What is the current status of trial NCT06980948?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-10. Estimated completion is 2028-07.
What conditions does trial NCT06980948 study?
This clinical trial studies the following conditions: Chronic Neuropathic Pain.
What interventions are being tested in trial NCT06980948?
The interventions under investigation include: Sham (No Treatment) (PROCEDURE), ST-503 (GENETIC).
Who is sponsoring clinical trial NCT06980948?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980948 being conducted?
This trial has 10 study locations across Arizona, Arkansas, Maryland, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia